COSTEM 2023 | Should patients with TP53-mutated MDS receive stem cell transplant?
Magnus Tobiasson
• 20 Oct 2023
In this video, Magnus Tobiasson, MBBS, Karolinska Institute, Solna, Sweden, shares some insights into whether patients with TP53-mutated myelodysplastic syndromes (MDS) should receive stem cell transplantation (SCT). Dr Tobiasson comments on the outcomes associated with patients who have single-hit versus double-hit TP53 mutation, and further highlights the challenges of treating this patient population. This interview took place at The 8th Congress on Controversies in Stem Cell Transplantation and Cellular Therapies (COSTEM 2023), held in Berlin, Germany.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
